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I. LIST OF ABBREVIATIONS 
 
AP Acute pancreatitis  
ARP Acute recurrent pancreatitis 
ARDS Acute respiratory distress syndrome 
AUC Area under the curve (the Receiver Operating Characteristic curve) 
BAP Before acute pancreatitis 
CI Confidence interval 
CFTR Cystic fibrosis transmembrane conductance regulator 
CHDI Complex Health Distance Index 
COVID-19 Coronavirus disease 2019 
CP Chronic pancreatitis 
CRP C-reactive protein 
CSSE Center for Systems Science and Engineering 
DAP During acute pancreatitis 
DM Diabetes mellitus 
DMC Data Monitoring Committee 
eCRF Electronic case report form 
GDP Gross Domestic Product 
HbA1c Hemoglobin A1c 
HPSG Hungarian Pancreatic Study Group 
HTG Hypertriglyceridemia 
IAP / APA International Association of Pancreatology / American Pancreatic Association 
IQR Interquartile range 
KETLAK Translational Action and Research Group against Coronavirus 
LOH Length of hospitalization 
OAP On admission with acute pancreatitis 
OR Odds ratio 
p P-value 
PCR Polymerase chain reactionPersonalized Health Education Against COVID-19 
PROACTIVE-19 Personalized Health Education Against COVID-19 
ROC Receiver Operating Characteristic 
ROS Reactive oxygen species 
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 
SC Steering Committee 
SD Standard deviation 
SE Standard error 
STROBE Strengthening the Reporting of Observational Studies in Epidemiology 
RCT Randomized controlled trial 
TM Translational medicine 
WHO World Health Organization 
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II. THESIS INTRODUCTION 
 
II.1. Translating scientific knowledge: Acute pancreatitis and Coronavirus disease 2019 
In this day and age, applying a scientific mindset and the prompt utilization of scientific 
results are vital, for the appropriate functioning and improvement of near all parts of life. 
However, the number of scientific publications is increasing at a rapid pace: with 291,806 
available on MEDLINE in the year of 1995 and 1,064,266 in 2015 – no doubt too much to be 
handled on a personal or even institutional level (1). In 2016, about 1.5 million people died in 
the European Union, who were less than 75 years old. Of these deaths, roughly 1 million would 
have been avoidable, either by applying timely and effective treatment or by better public 
health interventions (2). While of course, reasons for this astonishingly high number can be 
sought in economic allocation and education, a major determinant is the inadequate utilization 
of already acquired scientific results. There is a dire need for a centralized method that aids the 
incorporation of evidence into daily practice, and that converts it into a language that is 
understandable and usable not only by scientific professionals, but by governments and the 
general public as well. 
Translational medicine (TM) aims to ensure that scientific results are delivered or 
‘translated’ into general use (3). In medicine for example, this is done by following up 
promising basic science results with clinical studies, by standardizing the method of reporting 
in scientific papers, by updating guidelines as often and as thoroughly as possible, and 
promoting evidence-based patient management (4). And not only in medicine, but in any area 
of life, knowledge acquired this way should be presented both to decision makers and the 
general public, in a manner that they can best handle the information. It is also crucial to seek 
out gaps in the currently available evidence and conduct scientific experiments/systematic 
reviews to fill them (5). One such field where TM science is greatly needed is acute pancreatitis 
(AP): since 1965, the proportion of scientific papers focusing on AP among benign GI disorders 
dropped from 25.7% to 10.7%, and only 5.5% of registered trials were multicentric, making 
evidence scarce and poorly generalizable (6). 
AP is the sudden-onset inflammation of the pancreas, a common reason behind 
abdominal pain in the adult emergency department (7). In up to 25-30% of cases, severe disease 
course will occur, with a mortality rate as high as 40% - both severity and mortality could and 
should be diminished with improved care of these patients (8, 9). Due to remarkable efforts, 
the treatment of AP has undergone a substantial change in the past decades: instead of a nil per 
os diet or parenteral nutrition, clinical evidence now clearly prefers enteral feeding, or even 
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oral intake in case of tolerance (10). Guidelines also discourage the routine use of antibiotics 
(10, 11). Recent years’ basic science and clinical investigations are focusing on commonly 
encountered laboratory and anamnestic parameters that could help in establishing AP prognosis 
and the best choice of treatment on admission: pancreatotoxic agents. Pancreatotoxicity, a 
dose-dependent relationship with worsening clinical outcomes of AP, is already demonstrated 
in case of bile acids, alcohol and its metabolites, fatty acids and fatty acid ethyl esters (12-16) 
and presumed in case of smoking and several drugs (17, 18). We set out to examine – in keeping 
with the mentality of TM –  whether such a dose-dependent relationship exists with increasing 
serum glucose values, since basic science points towards the potential pancreatotoxic effects 
of hyperglycemia (19).  
However, in December 2019 the Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) pandemic hit, causing the Coronavirus Disease 2019 (COVID-19). It quickly 
became a humanitarian crisis the likes of which we have not seen perhaps since the Second 
World War. In little more than one year, there have been around 120 million confirmed cases 
of COVID-19 worldwide, resulting in almost 3 million deaths, mostly due to respiratory failure 
(20, 21). The world was struck unprepared for an outbreak and pandemonium of these 
measures. This made TM more necessary than ever: the scientific evidence, amassed in a hurry, 
needed to be evaluated and summarized in a hurry so that the government could react promptly 
and appropriately, minimizing the deleterious effects of the pandemic. It also became essential 
to assess, more swiftly than usual, where the literature was lacking, and design clinical or basic 
science experiments to fill the inherent voids. Thus, our focus partly shifted towards applying 
TM research for improving the COVID-19 pandemic.  
 
II.2. Aims of PhD work 
As the Director-General of Heim Pál National Pediatric Institute and the former State 
Secretary for Health of Hungary, it is of crucial importance to me that scientific results make 
their way into patient care as soon as possible. This not only improves the quality of care and 
helps avoid unnecessary deaths, but also greatly contributes towards building a more cost-
efficient healthcare system, which ultimately provides the basis for further improvement and 
better working conditions.  
In my PhD work I wanted to focus on different aspects of TM. We set out to analyze a 
prospective, international cohort of AP patients, and establish whether serum glucose predicts 
worse clinical outcomes or complications – since this information was yet uninvestigated. 
During the COVID-19 pandemic we provided systematic literature reviews and performed 
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mathematical modelling estimations to aid government decision makers. While exploring the 
available literature, we identified a gap in knowledge – this led to designing and initiating our 
randomized controlled trial (RCT), Personalized Health Education Against COVID-19 
(PROACTIVE-19), which is the first to investigate and provide a personalized, 
multicomponent lifestyle intervention program in a telephone-based manner, to help avoid the 
contraction and severe course of COVID-19.  
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III. GLUCOSE LEVEL INDEPENDENTLY AND DOSE_DEPENDENTLY WORSENS 
ACUTE PANCREATITIS: A COHORT ANALYSIS  
 
III.1. Introduction 
AP is the inflammation of the pancreas, most often caused by alcohol consumption and 
biliary obstruction (22). The incidence of AP is gradually increasing worldwide, now reported 
to be 4.6-100/100,000 in the general population (23, 24). The severity of the condition varies, 
with most cases being classified as mild, but in 15-30% and 10-20% of the cases, moderate and 
severe disease course will occur, resulting in longer hospitalization, organ failure (OF) and 
higher mortality (up to 40% in severe cases) (9, 25, 26).  
Szentesi et al. demonstrated that obesity, hypertension and hyperlipidemia are 
independent risk factors for several complications in AP. Furthermore, the more components 
of metabolic syndrome are present, the higher the risk for more severe disease outcomes (27). 
To acquire more knowledge on how different components of the metabolic syndrome affect 
the course of AP, the Hungarian Pancreatic Study Group (HPSG) has already investigated on-
admission serum triglyceride concentration. This prospective cohort study found that 
hypertriglyceridemia dose-dependently increases the severity and rate of AP complications 
(14). As a next step in filling the gaps of knowledge regarding the role of toxic metabolic 
factors in the clinical course, we set out to examine the outcome parameters of AP in the context 
of serum glucose concentration. 
Hyperglycemia is an established independent risk factor in numerous diseases. It 
independently predicts long-term mortality and is associated with a worse prognosis in acute 
myocardial infarction, irrespective of the presence of diabetes mellitus (DM) (28, 29). It is also 
associated with a higher rate of poor functional outcomes and less successful revascularization 
after acute ischemic stroke (30, 31). Furthermore, not only the acute elevations in serum 
glucose are of interest – studies describe chronic glucose dysregulation to be prognostic for 
mortality after acute myocardial infarction, both in diabetic and non-diabetic patients (32-34). 
In AP, the exact role of glucose dysregulation and its laboratory indicators is yet to be 
described. However, of the most widely used AP prognostic scoring systems, two (the Ranson 
and the Glasgow-Imrie) include a serum glucose concentration above 10 mmol/L, highlighting 
its potential role and association with severity (35).  
Our goal was to examine the presence of dose-dependency between glucose 
dysregulation and clinically important outcomes of AP in a large, multicenter, prospective 
cohort. In our current cohort analysis (1) previous glucose homeostasis, as assessed by 
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glycosylated hemoglobin (HbA1c) levels; and especially (2) serum glucose levels on 
admission; and (3) the highest glucose levels during hospitalization have shown dose-
dependent associations with key clinically important outcomes of AP. We also established 
hyperglycemia as an independent and dose-dependent risk factor for mortality. 
 
III.2. Methods 
Study design, data source 
This study presents a post-hoc analysis of a prospective, international, multicenter 
registry of AP patients, maintained by the HPSG. Participants were enrolled in the AP registry 
if they fulfilled the diagnostic criteria for AP as per the International Association of 
Pancreatology / American Pancreatic Association (IAP/APA) and HPSG guidelines (11, 36). 
They were followed up until the end of their AP associated hospital stay (until oral feeding was 
reinstated without symptoms and with the normalization of laboratory parameters). A list of 
study sites can be found in Table 1. Between 2012 and 2019, 2,461 adult (≥18 years old) AP 
patients' data were collected. To ensure data quality, a four-tier quality control system was 
applied, described in detail in a previous publication from the registry (37).  
 
Country City Institution n 
Belarus Gomel Gomel Regional Clinical Hospital 8 
Croatia Rijeka Clinical Hospital Center Rijeka 11 
Czech Republic Ostrava Vítkovice Hospital 11 
Finland Helsinki Helsinki University Central Hospital 25 
Hungary Békéscsaba Dr. Réthy Pál Hospital 62 
 Budapest Bajcsy-Zsilinszky Hospital 136 
  Buda Hospital of the Hospitaller Order of Saint John of God 5 
  Military Hospital – State Health Centre 1 
 Debrecen Department of Internal Medicine, University of Debrecen 168 
  Department of Surgery, University of Debrecen 7 
 Gyula Pándy Kálmán Hospital of County Békés 31 
 Kecskemét Bács-Kiskun County University Teaching Hospital 8 
 Makó Healthcare Center of County Csongrád 10 
 Miskolc Borsod-Abaúj-Zemplén County Hospital and University Teaching Hospital 11 
 Pécs First Department of Medicine, University of Pécs 819 
 Szeged First Department of Medicine, University of Szeged 263 
  Second Department of Medicine, University of Szeged 75 
  Department of Anesthesiology and Intensive Therapy, University of Szeged 10 
 Székesfehérvár Szent György University Teaching Hospital of County Fejér 383 
 Szentes Dr. Bugyi István Hospital 17 
 Szombathely Markusovszky University Teaching Hospital 17 
Japan Tokyo Keio University 2 
Lithuania Vilnius Vilnius University Hospital Santariskiu Klinikos 31 
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Romania Bucharest Central Military Emergency Hospital "Dr Carol Davila" 1 
 Targu Mures Mures County Emergency Hospital 56 
Russia St. Petersburg Saint Luke Clinical Hospital 28 
Spain 
Sant Pere de 
Ribes 
General Surgery, Consorci Sanitari del Garrof 26 
Turkey Istanbul Hospital of Bezmialem Vakif University, School of Medicine, Istanbul 20 
Ukraine Kiev Bogomolets National Medical University 8 
Total number of patients 2250 
Table 1: Centre distribution, cities, institutions. n: number of enrolled participants. 
 
Participants 
In the present analysis, we included 2,250 patients from the total of 2,461 participants 
in the AP registry with available data on (1) HbA1c any time during the hospitalization with 
AP and/or (2) on-admission serum glucose measurement and/or (3) at least two serum glucose 
measurements during hospitalization. 
Three variables were taken into account in dividing our examined cohort into 
subgroups. To observe the role of the glucose homeostasis preceding the admission with AP – 
'before AP' (BAP) – participants were divided into five groups based on their HbA1c: 6.50; 
6.51-7.00; 7.01-8.00; 8.01-9.00; ≥9.01%. To reflect the on-admission state – ‘on-admission 
AP’ (OAP) – seven groups were formed based on on-admission serum glucose levels: 3.99, 
4.00-5.99, 6.00-7.79, 7.80-11.09, 11.10-14.99, 15.00-19.99, ≥20.00 mmol/L. Seven groups 
were formed based on peak serum glucose during the hospital stay – 'during AP' (DAP) – 
among those patients who had at least two glucose measurements: 3.99, 4.00-5.99, 6.00-7.79, 
7.80-11.09, 11.10-14.99, 15.00-19.99, ≥20.00 mmol/L. These boundaries were chosen to 
reflect already established cut-offs (6.5% and 7% for HbA1c, 7.8 mmol/L and 11.1 mmol/L for 
glucose (38), participant and event numbers to maintain statistical power and equal increments 
to avoid the possibility of arbitrary cut-off selection. 
 
Variables 
 A complete list of collected variables – including data on laboratory parameters, 
complications, severity and mortality – is provided in our data quality table (Table 2). Local 
complications, systemic complications and severity were defined according to the revised 
Atlanta classification (39).  
Glucose measured only within the first 24 hours was accepted as on-admission glucose 
level. Venous measurements were preferred and accounted for most of the on-admission 
values, but results from capillary samples were also accepted. HbA1c measured any time 
 12
during the hospitalization was accepted for this analysis. 95% of measurements occurred within 
48 hours of hospitalization. 
 
EPIDEMIOLOGY, ETIOLOGY OVERALL UPLOADED DATA % 
Age 2250 2250 100 
Gender 2250 2250 100 
Etiology 2250 2250 100 
Average uploaded data 6750 6750 100 
    
PERSONAL MEDICAL HISTORY OVERALL UPLOADED DATA % 
Acute pancreatitis in the personal history 2250 2185 97 
Number of previous episodes among recurrent cases 493 457 93 
Chronic pancreatitis in the personal history 2250 2185 97 
Average uploaded data 4993 4827 97 
    
LABORATORY PARAMETERS  OVERALL UPLOADED DATA % 
Serum glucose on admission  2250 2129 95 
Hemoglobin A1c on admission 2250 752 33 
C-reactive protein (CRP) 2250 2197 98 
Average uploaded data 6750 5078 75 
    
OUTCOMES OVERALL UPLOADED DATA % 
Local pancreatic complications 2250 2232 99 
Peripancreatic fluid collection 2250 2232 99 
Pancreatic pseudocyst 2250 2232 99 
Pancreatic necrosis 2250 2231 99 
Organ failure 2250 2245 100 
Respiratory failure 2250 2243 100 
Heart failure 2250 2244 100 
Renal failure 2250 2244 100 
Length of hospitalization 2250 2250 100 
Severity (mild/moderately severe/severe) 2250 2250 100 
Mortality 2250 2250 100 
Average uploaded data 24750 24653 100 
    
TOTAL 43243 41308 96 
Table 2: Data quality table. 
 
Statistical analysis 
 For the descriptive analysis of categorical variables, case number and percentage were 
computed, while in the case of continuous variables, patient number, mean, standard deviation 
(SD), median, 25% and 75% quartiles (IQR) were calculated. To identify the three subcohorts' 
representativeness, we used the Chi-squared test in case of categorical data, the Student's t-test 
for normally distributed variables, and the Mann-Whitney U-test for non-normally distributed 
variables. In ‘Table 4’, groups with outlying age (Kruskal-Wallis test) and gender distribution 
(Fisher exact or Chi-squared test) were sought as well as trends in AP recurrence (RAP), 
chronic pancreatitis (CP), hyperlipidemia, DM in the medical history (Cochran-Armitage test 
 13
for trend) and AP episode number among RAP cases (Jonckheere-Terpstra trend test). The 
dose-dependent effects of HgA1c, on-admission and maximum glucose levels on the 
investigated outcomes, were tested using the Cochran-Armitage test for trend (in case of 
categorical variables) and the Jonckheere-Terpstra trend test (in case of continuous variables).  
To detect the predictive accuracy of HbA1c, on-admission glucose level and maximum 
glucose level on the mortality and severity, the Receiver Operating Characteristic Curve (ROC) 
was applied. To check the performance of the classification, we used Area Under the Curve 
(AUC) with 95% confidence intervals (CI) (depending on the AUC value, the accuracy of the 
test can be categorized as followed: 0.5–0.6 fail, 0.6–0.7 poor, 0.7–0.8 fair, 0.8–0.9 good and 
above 0.9 excellent). We calculated the potential best cut-off value as well. Odds ratios (OR) 
with 95% CI were calculated for severe AP cases and mortality. Binary logistic regression was 
used to test the independent prognostic role of the three investigated variables. The model 
contains the following parameters in all cases: age, gender, DM, AP etiology and HbA1c, on-
admission glucose level or maximum glucose level. All calculations were performed with the 
statistical software R, version 4.0.2 (R Core Team, 2020, Vienna, Austria) using the coin (v1.3-
4; Hothorn et. al., 2008), rcompanion (v2.3.27; Mangiafico, 2021), DescTools (v0.99.39; 
Signorell et. al., 2020), PMCMRplus (v1.9.0; Pohlert, 2021) and pROC (v1.17.0.1; Robin et. 
al. 2011) packages.    
 
Ethical approval 
 Ethical approval for the registry was granted in 2012 by the Scientific and Research 
Ethics Committee of the Medical Research Council (22254–1/2012/EKU). The registry 
protocol was approved by the institution's human research committee preceding the study 
initiation. It complies with the ethical guidelines of the Declaration of Helsinki, reaffirmed in 
2013. All participants provided written, informed consent for participation. 
 
Study reporting 
This study is reported according to the ’Strengthening the Reporting of Observational 




A total of 2,250 AP cases were analyzed. Table 4 contains the baseline information of 
participants in each subgroup of all three subcohorts (BAP, OAP and DAP). A statistically 
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significant trend of increasing proportion of hyperlipidemia and DM in the medical history 
with increasing HbA1c and glucose values was seen in all subcohorts. Among groups with 
different on-admission glucose values, significant age differences were noted, with the highest 
mean ages observed in groups 4-6 (glucose 7.8-19.99 mmol/L) and lowest in group 1 (glucose 
<4 mmol/L).  
BAP – HbA1c p 
Groups, 
HbA1c% 
≤6.50 6.51-7.00 7.01-8.00 8.01-9.00 ≥9.01 
 
n (%) 633 (84.0) 28 (3.7) 32 (4.2) 22 (2.9) 39 (5.2)  
Age (years), 
mean (SD) 
56.50 (16.76) 63.54 (12.20) 58.38 (12.76) 55.23 (11.59) 53.08 (13.86) 0.068 
Female, n (%) 260 (41) 13 (46) 10 (31) 4 (18) 11 (28) 0.078 














CP, n (%) 48 (8) 3 (11) 3 (9) 2 (9) 2 (5) 0.882 
DM, n (%) 74 (11.7) 17 (60.7) 28 (87.5) 18 (81.8) 35 (89.7) <0.001 
Hyperlip, n (%) 56 (9) 4 (16) 6 (21) 5 (26) 16 (43) <0.001 
OAP – on-admission serum glucose  p 
Groups, 
mmol/L 


























Female, n (%) 12 (57) 208 (44) 294 (42) 266 (43) 96 (43) 23 (34) 14 (34) 0.423 


















CP, n (%) 0 (0) 30 (6) 46 (7) 30 (5) 6 (3) 3 (4) 4 (10) 0.259 
DM, n (%) 2 (9.5) 24 (5.1) 62 (8.9) 121 (19.7) 105 (47.5) 49 (72.1) 30 (73.2) <0.001 
Hyperlip, n (%) 2 (13) 41 (10) 67 (11) 100 (19) 40 (21) 15 (25) 18 (50) <0.001 
DAP – peak serum glucose  p 
Groups, 
mmol/L 


























Female, n (%) 4 (67) 88 (47) 63 (44) 50 (41) 29 (37) 19 (44) 8 (50) 0.611 


















CP, n (%) 0 (0) 11 (6) 6 (4) 3 (2) 6 (8) 4 (9) 0 (0) 0.770 
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DM, n (%) 0 (0) 13 (7.0) 17 (11.9) 28 (22.8) 46 (58.2) 29 (67.4) 10 (62.5) <0.001 
Hyperlip, n (%) 2 (33) 18 (12) 21 (18) 19 (17) 23 (31) 13 (33) 6 (40) <0.001 
Table 4: Baseline characteristics of participants in each group of all three subcohorts. AP: acute 
pancreatitis; BAP: before AP; OAP: on-admission with AP; DAP: during AP; %: percentage; n: 
number; SD: standard deviation; p: P-value; RAP: recurrent acute pancreatitis; IQR: interquartile 
range; CP: chronic pancreatitis; DM: diabetes mellitus in the personal medical history; Hyperlip: 
hyperlipidemia in the personal medical history. 
 
Etiology distribution 
Figure 1 shows how different etiologies of AP were distributed across our examined 
subgroups. While most etiologies showed a balanced distribution, hypertriglyceridemia (HTG) 
increased in higher HbA1c and serum glucose groups, starting at HbA1c >7% in the BAP, and 
glucose >11.1 mmol/L in the OAP and DAP subcohorts.  
 
Figure 1: Etiology distribution. The top row shows the classification of groups. The middle row shows how 
etiologies within each group (etiologies add up to 100%). The bottom row shows group distribution within 
each etiology (groups add up to 100%). AP: acute pancreatitis; BAP: before AP; OAP: on-admission with 
AP; DAP: during AP; HbA1c: hemoglobin A1c; Glu: serum glucose; HTG: hypertriglyceridemia; bil: 
biliary, alc: alcoholic; comb: combined; idiop: idiopathic. 
 
BAP: pre-existing disturbance of glucose metabolism shows a trend of increasing AP 
severity and local complications. 
While no statistically significant differences were noted (p=0.394), a trend of increasing 
HbA1c and increasing AP severity was observed. AP severity was highest in Group 4 (21.4% 
moderate, 5.8% severe). HbA1c was directly associated with the length of hospitalization 
(LOH) (p<0.001) and maximal CRP (p<0.001), both peaking in group 4 probably due to the 
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higher proportion of moderate cases, but not with mortality, which was the greatest in Group 2 
(7.1%) (Figure 2).  
 
Figure 2: AP severity, mortality, length of AP-associated hospital stay, maximal CRP. AP: acute 
pancreatitis; BAP: before AP; OAP: on-admission with AP; DAP: during AP; HbA1c: hemoglobin A1c; 
Glu: serum glucose; LOH: length of AP associated hospitalization; max. CRP: maximal C-reactive protein.  
 
No trends were identified regarding systemic complications (respiratory, renal or heart 
failure) (p=0.959); the highest rate of organ failures was found in Group 3 (12.5%) (Figure 3). 
On the other hand, an increasing proportion of local complications (peripancreatic fluid, 
pancreas pseudocyst, pancreas necrosis) were seen with increasing HbA1c (Figure 4), without 




Figure 3: Systemic complications as defined by the revised Atlanta classification and Marshall criteria. The 
top row shows the classification of groups. The second row shows the percentage of AP cases with organ 
failure (one or more of lungs, heart and kidney). The third, fourth, and bottom rows show the percentage of 
AP cases with respiratory, heart and renal failure, respectively, in each group. AP: acute pancreatitis; BAP: 




Figure 4: Local pancreatic complications as defined by the revised Atlanta classification. The top row shows 
the classification of groups. The second row shows the percentage of AP cases with local complications (one 
or more of acute peripancreatic fluid collection, pancreas pseudocyst, pancreas necrosis – no distinction 
between acute necrotic collection and walled-off necrosis). The third, fourth, and bottom rows show the 
percentage of AP cases with acute peripancreatic fluid collection, pancreas pseudocyst and pancreas 
necrosis, respectively, in each group. AP: acute pancreatitis; BAP: before AP; OAP: on-admission with AP; 
DAP: during AP; HbA1c: hemoglobin A1c; Glu: serum glucose. 
 
The binary logistic regression did not show HbA1c to be an independent predictor of 
mortality (OR=1.211 (95% CI: 0.859-1.646), p=0.241) or severity (OR=1.028 (95% CI: 0.768-
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1.332), p=0.843) (Tables 7-8). The ROC analysis showed that HbA1c fails to predict mortality 
(AUC=0.545) and poorly predicts the severity of AP (AUC=0.601). 
 
BAP –HbA1c 
Outcome p (trend) p (1 vs 2) p (1 vs 3) p (1 vs 4) p (1 vs 5) 
Mortality 0.602 0.919 0.919 0.919 0.919 
Severity 0.394 0.995 0.884 0.884 0.884 
Etiology <0.001 0.627 0.627 0.825 0.627 
Length of hospitalization <0.001 0.302 0.057 0.072 0.164 
Maximal C-reactive protein <0.001 0.136 0.802 0.820 0.988 
OAP – on-admission serum glucose 
Outcome p (trend) p (2 vs 3) p (2 vs 4) p (2 vs 5) p (2 vs 6) p (2 vs 7) 
Mortality <0.001 0.059 0.22 <0.001 <0.001 0.084 
Severity <0.001 0.024 <0.001 <0.001 <0.001 <0.001 
Etiology <0.001 0.465 0.113 0.843 0.873 0.992 
Length of hospitalization <0.001 0.212 0.002 0.669 0.751 0.587 
Maximal C-reactive protein <0.001 0.299 0.077 0.322 0.462 0.578 
DAP – peak serum glucose 
Outcome p (trend) p (2 vs 3) p (2 vs 4) p (2 vs 5) p (2 vs 6) p (2 vs 7) 
Mortality 0.001 0.239 0.059 0.16 0.027 0.002 
Severity <0.001 0.023 <0.001 <0.001 <0.001 <0.001 
Etiology <0.001 0.899 0.260 0.069 0.899 0.330 
Length of hospitalization <0.001 0.008 0.011 0.002 <0.001 <0.001 
Maximal C-reactive protein <0.001 0.151 0.239 0.801 0.773 0.892 
Table 5: P-values corresponding to trends (Cochran-Armitage test for trend and Jonckheere-Terpstra test) 
and intergroup differences in mortality, severity, etiology, length of hospitalization and maximal C-reactive 
protein. Values below 0.05 (bold) indicate statistical significance. BAP: before AP; OAP: on-admission with 
AP; DAP: during AP; p: P-value.  
 
OAP and DAP: on-admission and peak glucose levels demonstrate a dose-dependent 
association with worse AP outcomes (severity, mortality, complications, LOH, maximal 
CRP). 
A dose-dependent association was seen between on-admission glucose levels, peak in-
hospital glucose levels and: severity (p<0.001 in both OAP and DAP), mortality (p<0.001 OAP 
and DAP), LOH (p<0.001 OAP and DAP), maximal CRP (p<0.001 OAP and DAP) (Figure 
2), systemic complications (p<0.001 OAP and DAP; Figure 3) and local complications 
(p<0.001 OAP and DAP; Figure 4).  
The group with a peak in-hospital glucose ≥20 mmol/L (Group 7) noted the highest 
severity (37.5% moderate, 25.0% severe), mortality (12.5%), systemic (43.8%) and local 
complications (62.5%). While similarly, on-admission glucose Group 7 saw the highest rate of 
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local complications (36.6%), Group 6 (serum glucose 15 – 19.99 mmol/L) had the highest 
severity (38.2% moderate, 8.8% severe), mortality (8.8%), and rate of systemic complications 
(14.7%).  
The binary logistic regression established both on-admission and peak in-hospital 
serum glucose to be independently associated with mortality (OR=1.133 (95% CI: 1.064-
1.204), p<0.001 and OR=1.089 (95% CI: 1.020-1.161), p=0.006, respectively) and severity 
(OR=1.131 (95% CI: 1.078-1.186), p<0.001 and OR=1.093 (95% CI: 1.039-1.152), p<0.001, 
respectively) (Tables 7-8). The ROC analysis showed on-admission glucose to be a poor 
predictor of mortality (AUC=0.636 for an estimated cut-off of 10.635 mmol/l) and severity 
(AUC=0.671 for an estimated cut-off of 9.435 mmol/l). An on-admission glucose >10 mmol/l 
had an OR of 3.140 (95% CI: 2.106-4.682) for severe AP and an OR of 2.666 (95% CI: 1.587-
4.478) for mortality. The ROC analysis indicated that peak in-hospital glucose is a fair 
predictor of mortality (AUC=0.703 for an estimated cut-off of 6.665 mmol/l) and severity 
(AUC=0.732 for an estimated cut-off of 7.355 mmol/l). A peak in-hospital glucose >7 mmol/l 
had an OR of 14.490 (95% CI: 4.443-47.264) for severe AP and an OR of 4.750 (95% CI: 
1.370-16.476) for mortality. 
Hypoglycemia (Group 1) was associated with a higher rate of organ failure and maximal 
CRP in both the OAP and DAP subcohorts and higher severity only in the DAP subcohort. 
Increased mortality, LOH or local complications were not seen. 
 
Additional trends, intergroup differences 
The results of additional trend tests not discussed in the article's main body and P-values 
corresponding to intergroup differences for all examined outcomes can be found in Tables 5 
and 6. 
BAP –HbA1c 
Complications p (trend) p (1 vs 2) p (1 vs 3) p (1 vs 4) p (1 vs 5) 
Local pancreatic 
complications 
0.122 0.892 0.892 0.892 0.892 
Peripancreatic fluid 
collection 
0.033 0.887 0.753 0.679 0.753 
Pancreatic pseudocyst 0.478 0.985 0.985 0.985 0.985 
Pancreatic necrosis 0.536 0.830 0.830 0.883 0.883 
Organ Failure 0.959 0.849 0.849 0.849 0.849 
Respiratory failure 0.697 0.849 0.849 0.849 0.849 
Heart Failure 0.886 0.618 0.618 0.779 0.989 
Renal failure 0.846 0.618 0.618 0.797 0.836 
OAP – on-admission serum glucose 
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Complications p (trend) p (2 vs 3) p (2 vs 4) p (2 vs 5) p (2 vs 6) p (2 vs 7) 
Local pancreatic 
complications 
<0.001 0.024 <0.001 <0.001 <0.001 0.005 
Peripancreatic fluid 
collection 
<0.001 0.003 <0.001 <0.001 <0.001 <0.001 
Pancreatic 
pseudocyst 
0.041 0.722 0.722 0.607 0.607 0.722 
Pancreatic necrosis <0.001 0.007 <0.001 <0.001 <0.001 0.007 
Organ Failure <0.001 0.075 <0.001 <0.001 <0.001 <0.001 
Respiratory failure <0.001 0.067 <0.001 <0.001 <0.001 <0.001 
Heart Failure <0.001 0.164 0.117 0.001 0.007 0.005 
Renal failure <0.001 0.062 0.002 0.002 0.002 <0.001 
DAP – peak serum glucose 
Complications p (trend) p (2 vs 3) p (2 vs 4) p (2 vs 5) p (2 vs 6) p (2 vs 7) 
Local pancreatic 
complications 
<0.001 0.062 0.003 0.003 0.003 0.005 
Peripancreatic fluid 
collection 
<0.001 0.023 <0.001 <0.001 <0.001 <0.001 
Pancreatic 
pseudocyst 
0.118 0.969 0.728 0.728 0.969 0.969 
Pancreatic necrosis 0.002 0.081 0.008 0.011 0.008 0.966 
Organ Failure <0.001 0.643 <0.001 0.004 0.016 <0.001 
Respiratory failure <0.001 0.179 <0.001 <0.001 <0.001 <0.001 
Heart Failure 0.004 0.875 0.549 0.342 0.076 0.431 
Renal failure 0.036 0.925 0.230 0.927 0.230 0.258 
Table 6: P-values corresponding to trends (Cochran-Armitage test for trend) and intergroup differences 
(Chi-squared or Fisher exact test) in local and systemic complications. Values below 0.05 (bold) indicate 
statistical significance. BAP: before AP; OAP: on-admission with AP; DAP: during AP; p: P-value.  
 
BAP –HbA1c 
Predictor β SE p OR 95% CI 
Age per years 0.0524 0.016 <0.001 1.054 1.023-1.088 
Gender female (vs. male) -0.861 0.496 0.082 0.423 0.150-1.074 
Diabetes Mellitus <0.001 -1.355 0.710 0.056 0.258 0.056-0.934 
HbA1c per 1.0% 0.192 0.163 0.241 1.211 0.859-1.646 
Etiology 
alcoholic (vs. biliary) 0.809 0.705 0.251 2.246 0.521-8.857 
HTG (vs. biliary) 2.398 0.849 0.005 11.004 1.857-56.432 
Combined (vs. biliary) 2.262 0.686 <0.001 9.598 2.407-37.430 
Idiopathic (vs. biliary) 1.689 0.564 0.003 5.413 1.824-17.319 
Other (vs. biliary) -15.169 1160.223 0.990 2.584x10-7 0.000-1.545x1020 
OAP – on-admission serum glucose 
Predictor β SE p OR 95% CI 
Age per years 0.048 0.010 <0.001 1.050 1.030-1.071 
Gender female (vs. male) -0.210 0.303 0.488 0.811 0.444-1.463 
Diabetes Mellitus <0.001 -0.984 0.399 0.013 0.374 0.162-0.784 
On-admission glucose per 1 mmol/l 0.1252 0.031 <0.001 1.133 1.064-1.204 
Etiology alcoholic (vs. biliary) 1.273 0.438 0.004 3.570 1.504-8.456 
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HTG (vs. biliary) 1.209 0.749 0.106 3.351 0.643-12.973 
Combined (vs. biliary) 1.723 0.539 0.001 5.603 1.821-15.549 
Idiopathic (vs. biliary) 1.220 0.352 <0.001 3.388 1.712-6.872 
Other (vs. biliary) 0.211 0.768 0.784 1.235 0.191-4.554 
DAP – peak serum glucose 
Predictor β SE p OR 95% CI 
Age per years 0.025 0.017 0.142 1.025 0.993-1.061 
Gender female (vs. male) -0.125 0.528 0.813 0.882 0.305-2.482 
Diabetes Mellitus <0.001 -1.321 0.720 0.067 0.267 0.052-0.950 
Peak glucose per 1 mmol/l 0.085 0.031 0.006 1.089 1.020-1.161 
Etiology 
alcoholic (vs. biliary) 0.365 0.808 0.652 1.440 0.262-6.845 
HTG (vs. biliary) 0.642 1.199 0.593 1.900 0.089-15.420 
Combined (vs. biliary) 1.261 0.896 0.159 3.528 0.465-18.498 
Idiopathic (vs. biliary) 0.713 0.593 0.229 2.040 0.633-6.802 
Other (vs. biliary) -15.822 1385.218 0.991 1.344x10-7 0.000-3.693x1030 
Table 7: Binary logistic regression for mortality, accounting for age, gender, diabetes mellitus, acute 
pancreatitis etiology and: on-admission hemoglobin A1c in the BAP grouping, on-admission serum glucose 
in the OAP grouping, highest in-hospital serum glucose in the DAP grouping. AP: acute pancreatitis; BAP: 
before AP; OAP: on-admission with AP; DAP: during AP; HbA1c: hemoglobin A1c; HTG: 
hypertriglyceridemia; β: Beta coefficient; SE: standard error; p: P-value; OR: odds ratio; 95% CI: 95% 
confidence interval.  
 
BAP –HbA1c 
Predictor β SE p OR 95% CI 
Age per years 0.045 0.012 <0.001 1.046 1.021-1.074 
Gender female (vs. male) -0.252 0.361 0.486 0.777 0.376-1.565 
Diabetes Mellitus <0.001 -0.310 0.479 0.518 0.734 0.273-1.807 
HbA1c per 1.0% 0.028 0.139 0.843 1.028 0.768-1.332 
Etiology 
alcoholic (vs. biliary) 0.491 0.519 0.345 1.634 0.562-4.414 
HTG (vs. biliary) 2.271 0.624 <0.001 9.690 2.737-32.572 
Combined (vs. biliary) 1.295 0.579 0.025 3.651 1.076-10.877 
Idiopathic (vs. biliary) 0.306 0.478 0.522 1.358 0.501-3.359 
Other (vs. biliary) -1.153 1.048 0.271 0.316 0.017-1.628 
OAP – on-admission serum glucose 
Predictor β SE p OR 95% CI 
Age per years 0.031 0.007 <0.001 1.032 1.017-1.047 
Gender female (vs. male) 0.007 0.232 0.976 1.007 0.638-1.587 
Diabetes Mellitus <0.001 -0.626 0.291 0.031 0.535 0.295-0.927 
On-admission glucose per 1 mmol/l 0.123 0.024 <0.001 1.131 1.078-1.186 
Etiology 
alcoholic (vs. biliary) 0.625 0.335 0.062 1.868 0.958-3.581 
HTG (vs. biliary) 1.647 0.438 <0.001 5.190 2.130-11.992 
Combined (vs. biliary) 0.993 0.441 0.024 2.699 1.071-6.160 
Idiopathic (vs. biliary) 0.549 0.271 0.043 1.732 1.012-2.941 
Other (vs. biliary) -0.362 0.616 0.557 0.697 0.165-2.007 
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DAP – peak serum glucose 
Predictor β SE p OR 95% CI 
Age per years 0.009 0.011 0.422 1.009 0.988-1.032 
Gender female (vs. male) -0.096 0.349 0.783 0.909 0.454-1.797 
Diabetes Mellitus <0.001 -0.888 0.431 0.039 0.412 0.167-0.919 
Peak glucose per 1 mmol/l 0.089 0.026 <0.001 1.093 1.039-1.152 
Etiology 
alcoholic (vs. biliary) -0.009 0.560 0.987 0.991 0.313-2.890 
HTG (vs. biliary) 1.369 0.621 0.028 3.932 1.115-13.092 
Combined (vs. biliary) 0.622 0.702 0.375 1.862 0.391-6.680 
Idiopathic (vs. biliary) 0.668 0.408 0.102 1.951 0.878-4.414 
Other (vs. biliary) -0.535 0.802 0.505 0.586 0.086-2.331 
Table 8: Binary logistic regression for severity, accounting for age, gender, diabetes mellitus, acute 
pancreatitis etiology and: on-admission hemoglobin A1c in the BAP grouping, on-admission serum glucose 
in the OAP grouping, highest in-hospital serum glucose in the DAP grouping. AP: acute pancreatitis; BAP: 
before AP; OAP: on-admission with AP; DAP: during AP; HbA1c: hemoglobin A1c; HTG: 
hypertriglyceridemia; β: Beta coefficient; SE: standard error; p: P-value; OR: odds ratio; 95% CI: 95% 
confidence interval.  
 
III.4. Discussion 
 Pancreatic inflammation together with cell death are the end steps of an intricate 
interplay of events – as described by the model of "multiple hits on multiple targets", various 
signaling pathways are activated resulting in the clinical entity of AP (41). The main alterations 
observed inside the acinar cells are the increase in calcium concentration, increase in the 
number of lysosomes and zymogen granules, leading to mitochondrial dysfunction, 
endoplasmic reticulum stress and premature trypsinogen activation (24). These changes can be 
initiated either by ductal obstruction (42, 43) or by the direct acinar effect of various 
pancreatotoxic agents (12, 44). The most common culprits responsible for pancreatic toxicity 
are bile acids, alcohol and its metabolites, but fatty acids and fatty acid ethyl esters are also 
described to initiate the above-mentioned pathways in a dose-dependent manner (12, 13, 15, 
16, 45). And observations go beyond basic science – cohort studies also describe 
hypertriglyceridemia to be dose-dependently associated with increasing severity and rate of 
complications (14).   
There is a layered relationship between DM and AP. In severe AP cases with substantial 
pancreatic necrosis, β-cell loss can lead to the development of DM (46). But even in moderate 
and mild AP, impaired β-cell function and insulin resistance are observed in more than 30% of 
the cases (47), leading to a two-fold risk for developing diabetes after experiencing a single 
episode (48, 49). At the same time, cohort studies described a 1.5-3 times higher risk of AP 
among type 2 diabetic individuals – a possible reason behind this are the overlapping risk 
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factors (e.g., obesity and hypertriglyceridemia) (27, 50-52). Another key point in the many 
intersections between these two conditions is the higher severity of AP in individuals with pre-
existing DM. A meta-analysis of cohort studies described a significantly higher risk of 
complications, intensive care unit (ICU) admission, and mortality as compared to non-DM 
individuals (53). In a pancreatitis rat model, streptozotocin-induced hyperglycemia 
significantly reduced the pancreatic amylase content, which the investigators believed to be 
due to the direct harmful effects on acinar cells (19). This indicates that glucose itself could be 
involved in AP as a potential pancreatotoxic agent. So far, clinical investigations were limited 
to discussing the role of DM – and neglected the glycemic state.  
Our study is the first to focus on how alterations of the glucose homeostasis affect 
clinically relevant outcomes of AP. We found on-admission and peak in-hospital serum glucose 
concentrations to have a statistically significant dose-dependent relationship with AP severity, 
mortality, LOH, maximal CRP, systemic and local complications. Both these variables are 
independently (accounting for DM, age, gender and etiology) associated with AP severity and 
mortality, a peak in-hospital glucose >7 mmol/l making severe AP almost 15 times and death 
almost five times more likely. While statistically significant dose-dependency was only 
identified with LOH and maximal CRP in case of HbA1c, a trend of increasing severity and 
rate of local complications was also noted. In light of the currently available scientific literature 
on the matter, these findings strongly suggest that glucose has a direct pancreatotoxic effect. 
The main step in glucose-mediated cytotoxicity is the intracellular increase in reactive 
oxygen species (ROS) (54). ROS also have a central role in the process of pancreatic 
inflammation, promoting pathways towards mitochondrial dysfunction, cell death and 
inflammation in a self-amplifying manner (55, 56). Another way in which glucose could 
potentially harm the pancreas is via influencing its vasculature. Increased ROS production 
inside endothelial cells in hyperglycemia causes microvascular endothelial dysfunction by 
decreasing nitric oxide availability and increasing permeability, leukocyte adhesion and 
procoagulant activity (57). Such microvascular disturbances contribute to the inflammation of 
the ischemia-sensitive pancreas (58). 
While we demonstrated dose-dependency and independent association with AP severity 
and mortality, the whole extent of worsening AP outcomes should not exclusively be attributed 
to glucose. As hyperglycemia often presents in the context of DM and metabolic syndrome, 
the prevalence of these conditions accumulates with increasing glucose concentration. Here, 
an increased rate of hypertriglyceridemia, cholelithiasis and possibly β-cell hypertrophy 
facilitate the formation of AP (59-62), with hypertriglyceridemia also being associated with a 
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more severe disease course (63). Accordingly, in our cohort, we observed a growing proportion 
of hypertriglyceridemia with increasing serum glucose and HbA1c values. Severity and 
mortality however, only increased parallelly with on-admission and peak glucose, but not 
HbA1c. This might partly be due to the low participant and event numbers in the higher HbA1c 
groups – 83.9% of cases had HbA1c values below 6.5% - and partly because HbA1c indicates 
the preceding three months' glucose homeostasis, not necessarily reflecting glucose levels at 
the time of the AP. All in all, the fact that the proportion of hypertriglyceridemia increased 
with all three variables, but severity and mortality only did so with serum glucose further 
reinforces the results of our binary logistic regression, underlining the potential pancreatotoxic 
nature of hyperglycemia.  
Apart from signaling a transient dysregulation, on-admission and especially peak in-
hospital hyperglycemia could also be caused by new-onset pancreatogenic DM. A common 
concern is that AP episodes that are more severe might have a higher likelihood of substantial 
β-cell death; this could increase the proportion of severe cases among those with high glucose 
values. However, clinical studies do not support the association between AP severity and newly 
diagnosed DM (64). DM and thus pathological serum glucose values can be overrepresented 
in CP cases, 25-80% of CP patients develop DM (65). Acute exacerbations in people with CP 
are known to be less severe (66), possibly decreasing severity and mortality in higher HbA1c 
and glucose groups, but we found a balanced distribution of CP among groups. 
 
Strengths and limitations 
Strengths: To our knowledge, this is the first clinical study focusing on the role of glucose 
homeostasis in AP, observing the presence of dose-dependency with its clinically important 
outcomes. We succeeded in demonstrating dose-dependency and independent association with 
AP severity and mortality for both on-admission and peak in-hospital serum glucose. The data 
source is a prospective cohort, boasting an impressive number of patients from multiple centers 
worldwide, enhancing the applicability of our results. As described in the 'Methods' section we 
also applied a rigorous quality control system, to ensure the validity of our data.  
Limitations: A limitation to our study is that glucose values cannot be separated from the 
underlying DM and metabolic comorbidities, possibly influencing outcomes. Nevertheless, we 
feel that they should not be separated: although more likely in diabetic patients, hyperglycemia 
can occur and elicit pancreatotoxicity in any subpopulation. Distinguishing exactly what causes 
the dysregulation in each patient was beyond the scope of this clinically oriented cohort 
analysis – an interesting question nonetheless for future studies. Another limitation is that DM 
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is overrepresented in the BAP subcohort (23.0% of HbA1c measurements happened in known 
diabetic participants). Only 26.5% of patients had at least two glucose measurements during 
their hospitalization, predominantly those with abnormal on-admission values (44.7%). As 
mentioned in the 'Methods' section, capillary glucose values (although representing the 
minority of cases) were also accepted. In an attempt to form groups based on established cut-
offs and equal increments, some groups ended up having relatively low participant numbers, 
weakening statistical power. 
 
Implications 
Prevention: Increased HbA1c was associated with higher severity and a higher rate of local 
complications. Maintaining a normal glucose homeostasis might reduce the risk of these 
events. 
Prognosis: Increased on-admission glucose has a dose-dependent association with increasing 
severity, mortality, LOH and complications of AP.  
Prompt treatment: High peak glucose is dose-dependently associated with a higher rate of 
severe cases, mortality, systemic complications and increased LOH. Hyperglycemia does not 
necessarily present on admission, monitoring serum glucose during the course of AP is crucial. 
Adequate in-hospital control of hyperglycemia can greatly contribute to the treatment of AP.  
 
IV. TRANSLATIONAL MEDICINE IN THE COVID-19 PANDEMIC 
 The arrival of the COVID-19 pandemic and the ensuing humanitarian crises 
immediately shifted our focus. Through tremendous efforts, we formed an interdisciplinary 
team applying the methods of TM. Our ultimate goal was to aid the Hungarian government in 
this desperate and seemingly hopeless situation to best handle the pandemic, so together, we 
can achieve the best possible medical and economical results. We mathematically modelled 
intensive care unit (ICU) capacity, regional differences, Gross Domestic Product (GDP) loss, 
etc. and forwarded the information to policy-makers. During our systematic review of the 
available literature, we noted the need for RCTs testing telephone-based lifestyle interventions. 
We designed and initiated the PROACTIVE-19 trial to fill this void. 
 
IV.1. TRANSLATING SCIENTIFIC KNOWLEDGE TO GOVERNMENT DECISION 
MAKERS: MATHEMATICAL MODELLING STUDY  
IV.1.1. Introduction 
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TM is an enterprise that aims to translate scientific evidence for community benefits in 
order to elevate the health level of a society (67, 68). It is essential to find a way to translate 
scientific findings into digestible information for the general public, healthcare professionals, 
insurance companies, leaders of institutions and governmental policymakers (69-72). This 
latter has particular importance in times of epidemics and humanitarian crises, when 
government officials have a short time to make critical decisions (73, 74). The foretelling of 
future scenarios and forwarding evidence-based information for policymakers are paramount 
during pandemics (75-78).  
Unsurprisingly, countries like Israel, Switzerland, Germany, Canada, South Korea (79-
82), handled the COVID-19 outbreak with better outcomes, where the science level is high and 
the government listened to scientists. In Italy and Spain, where the scientific activity is lower 
(83) and in the USA where the governments failed to listen to scientists early enough, the initial 
consequences of the pandemics were more devastating (84).      
In Hungary, the first COVID-19 patient was identified on the 4th of March, 2020. 
Wisely, the Hungarian government immediately started a conversation with expert scientists 
and health care professionals to assess the potential future scenarios before decisions on the 
epidemic were taken. Our Translational Action and Research Group against Coronavirus so 
called KETLAK released and handed two documents directly to the National Epidemiological 
Policy-Making Body which was lead by the Prime Minister of Hungary to help the decision 
making process related to the Easter holidays and gradual normalization of public life. Here 
we summarize the scientific methodology, results, and suggestions which had a vital impact on 
the Hungarian government’s decisions.    
 
IV.1.2. Methods 
To support the epidemiological decision-making process, we performed several 
scientific data analyses and formulated them into three chapters: 1) results, 2) problems, 3) 
suggestions. The two materials were submitted on the 9th and 19th of April and one of the 
members of KETLAK introduced the conclusions personally (85).   
 
Modeling the ICU bed capacity in Hungary. 
In our mathematical model we calculated that above 3,000 beds, due to the significant 
decrease of human capacity, i.e., the effectiveness of treatments, the mortality rate will 
significantly increase as we saw it in Wuhan, Italy or New York (86-88). Therefore up to 3,000 
 28
ICU beds we calculated with 30% mortality, whereas above 3,000 ICU beds with 60% 
mortality.  
 
Mathematical modeling of the COVID-19 epidemic in Hungary 
To predict the possible outcome over time for various R metrics, data was collected on 
the 8th of April 2020 from the official Hungarian data resource site (koronavirus.gov.hu). Input 
parameters of the model included the actual R metric, the total numbers of infected cases up to 
the 8th of April and the available and occupied ICU beds. The model was generated both for 
the whole country and separately for all its main regions. In the case of Budapest, for example, 
R was estimated to be 1.25, the number of reported infected cases 552, and the available ICU 
beds is 750. Additional parameters were set based on the available international data such as 
the rate of how many of infected cases would end up in the intensive care unit (2-4%), the 
number of days one patient would spend there (~2 weeks) and the total death rate of ICU 
patients (30%) (87).  
 
Modeling the regional differences in Hungary: the complex health distance index (CHDI) 
For the measurement of the regional differences of health status in Hungary, we adopted 
and restructured the approach of the functional distance index from the economic analyses (89, 
90). Our Complex Health Distance Index (CHDI) in addition to the availability of the health 
care institutions (physical distance component) takes into account, the social, economic and 
institutional characteristics of the analyzed regional units (settlement, district, county etc.) and 
the main indicators of the health status of the local (91). 
 
Modeling the GDP loss, economic crisis management, and competitiveness 
Our mathematical model focuses on quantifiable variables, and takes into account data 
of the previous years and currently available data. It means that it works with the average per-
capita GDP, the population of the given region and the healthcare data related to morbidities 
and fatalities. To model the GDP loss for the five main Hungarian regions, GDP was corrected 
and normalized by the estimated death rate, predicted by the first model, for all the main 
Hungarian regions separately. 
 
Modelling the impact of closing and reopening elementary schools 
Classic SIR (susceptible-infected-recovered) simulation using EpiFire 3.34 API 
software was applied to model contact network of epidemic transmission using the ‘small-
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world-like’ model to compare epidemic scenarios for closing and reopening schools in the 
current COVID-19 pandemic. This model was developed by Carrat et al.  and used as a flexible 
tool to determine interventions in influenza pandemic (92). The model captures changing 
disease transmission dynamics (93).  
 
Modeling the optimal screening strategy in Hungary 
A Hungarian-specific model was developed to estimate the optimal screening 
strategies, i.e. the number of screening tests needed for recommendations to keep R under a 
required level. These were calculated for all regions, the individual counties of the region, and 
the whole country under various cases of lifting the socio-economic lockdown. The calculation 
was made in R software (94).  
 
IV.1.3. Results 
First we modeled different scenarios to the decision-makers in which we estimated the 
number of deaths in relation to the predicted number of new cases (number of people infected) 
together with the modeled numbers of available and occupied ICU beds. The best case scenario 
for the whole country, using R metrics estimated on the 8th of April, shows that maintaining 
the restriction would result in a total of 20,000 new cases at its peak, there would still have 
enough number of ICU beds to cover the needs for the most serious cases, and therefore, the 
total death would be kept under 1,500 (Figure 5A). The worst case scenario was modeled for 
higher R metrics (R=2.2), i.e., what would happen for the whole country in case of removing 
all the restrictions. The numbers indicate that within three weeks there would not be enough 
ICU beds, as we would have been sort of 40,000 at the peak, the number of infected cases 
would have reached 550,000 and the number of deaths was predicted to be 70,000 (Figure 5B).  
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Figure 5. Mortality scenarios for the whole country with 2 different R metrics. (A) Best-case scenario with 
R set to 1:3. (B) Worst-case scenario with R set to 2.2. In both cases, the left side of the y-axis stands for 
numbers presented by the dashed-line curves, such as the total death, occupied and available ICU beds (in 
red, orange and gray, respectively), the right side of the y-axis stands for the numbers presented by the single 
normal line curve (ie, the predicted new cases [in blue]). The numbers of available and occupied ICU beds 
are in close connection and if one is decreasing, the other is increasing by the same number. When no more 
ICU beds are available, the number will go to less than zero, showing the lack of ICU beds. ICU: intensive 
care unit 
 
Then we investigated the regional differences in Hungary. Our mathematical models 
clearly indicated that Hungary could not be handled as a whole, but rather regional differences 
should be taken into account. It was clearly seen when we looked for each region separately 
the regional distribution of people over 65 years, the differences between the ICU capacities, 
the estimated GDP loss due to lack of labor force, and the inequalities in CHDI. Therefore the 
earier modeled best case scenario was also modeled for each region separately. Although we 
can see big differences between the regions, there would be enough hospital capacity in case 
of maintaining the socio-economic lockdown. The worst case scenario for each region 
separately indicates that none of the region would have enough ICU bed capacity. Moreover, 
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number of ICU beds. As expected, regions where these numbers reach earlier the limits would 
suffer the most in mortality.  
Next we provided disease transmission simulations to help crucial decisions on closing 
and reopening elementary schools. The disease transmission simulation model of Budapest can 
be seen in Figure 6. According to our calculations for Budapest in the case of the R=2.2 or 
higher, large epidemic size classes are prone to face fast disease transmission with relatively 
high frequency. In this case, the chance for an effective health policy intervention to suppress 
or mitigate the epidemic cycle is very low. Thereby we don’t suggest early or complete release 
of school closures, moreover we support a prolonged and stepwise opening towards the contact 
education in the elementary schools. The epidemic size estimations for the county seats seem 
to be more controllable with smaller subgroups develop the epidemic outbreak with higher 
frequency even in our baseline R=2.2 scenario. Thus there is a real likelihood to carry out the 














Figure 6. Impact of closing and reopening elementary schools in Budapest. Simulation models of disease 
transmission dynamics to demonstrate the COVID-19 outbreak in Hungary with the reproduction rate (R) 
= 2.2 (A) and the effect of closing (R= 1.4) (B) and reopening (R= 1.7) (C) elementary educational 
institutions in Budapest. (n = 200 simulations were run for each R scenario.) 
 
Since it was earlier suggested that higher number of tests results in a lower rate of 
mortality, we compared the number of tests performed in different countries. We can clearly 
conclude that the amount of daily testing highly determines the rate of subsequent mortality  
Figure 7A show that the amount of tests are very low in Hungary. Internationally 
available data show that Germany is one of the most efficient European countries to keep the 
mortality rate low. Using this number as a reference point, we have estimated the optimal 
number of tests needed in Hungary. Figure 7B. After that, numbers from Figure 7B were 
corrected for each county by regional hospital capacities, such as ICU beds, the GDP, and the 
CHDI (Figure 7C). Using these parameters, Figure 7D and 7E show how many tests would be 
needed in case of easing the restrictions by reopening the primary schools and completely 
reopening the whole country, respectively.  
 
Figure 7. Current testing in Hungary and in Germany. (A) Number of tests for all counties (for 100,000 
people) in Hungary on April 8, 2020. (B) Required number of tests for the regions if the German testing rate 
(50,000 tests per day) is taken as a reference. Suggested testing in Hungary calculated from the German 
testing number modified by the Hungarian ICU capacity, GDP and CHDI. The optimal number of tests 
based on the German testing rate, corrected by ICU capacity, GDP, and CHDI, in case of maintaining the 
restrictions (C), reopening primary schools (D), and removing all the restrictions except for the elderly (E). 
All numbers are corrected to the population of the given county. CHDI: Complex Health Distance Index; 
GDP: gross domestic product; ICU: intensive care unit. 
 
IV.1.4. Discussion 
The tasks of the scientific community include recognizing challenges in specific 




EDURING RESTICTIONS SCHOOL OPENING TOTAL OPENING
CURRENT HUNGARIANA
 33
evidence-based summaries of scientific results and communicating them in understandable 
language to the target groups where the knowledge can be utilized. The latter includes two-
way communication between the scientific community and government decision makers as 
well. An excellent example of this is the European Commission's Scientific Advice Mechanism 
system, in which the High Level Group of Scientific Advisors and Academies provide timely, 
independent scientific advice to the highest policy level in Europe and for the wider public to 
support their decision making (95, 96). This is especially important in situations where there is 
a short time to make key decisions that affect the daily lives and health of the population. In 
this article we present the preparation and summary of two important scientific materials and 
their effects in Hungary. 
There were recent epidemics caused by members of the coronavirus family. These 
epidemics had different dynamics and characteristics. The deadly outbreak of Severe Acute 
Respiratory Syndrome (SARS) in 2003  in Toronto, which claimed 43 lives among 253 infected 
patients,  was successfully contained by a rapid and efficient response by scientists and 
politicians fighting it shoulder to shoulder (97-99). The successful strategy against the current 
SARS-CoV-2 pandemics of South Korea stemmed from their recent bitter experience with the 
Middle East respiratory syndrome (MERS) outbreak. They learned the lesson that only 
scientific evidence could guide political decisions in an epidemic (100). 
Here we show direct scientific evidence that there is a large difference between the 
territorial patterns and the economic, social and healthcare structures in Hungary, which can 
have an impact on the spread of the pandemic. Therefore, besides using the available 
international data we counted the major influencing factors such as age differences, ICU bed 
availability, and the differences between the CHDI separately in our later analysis. Since a 
pandemic is not only health but also a socio-economic crisis, we took the regional GDP 
differences into account as well. It was also important since the socio-economic crisis 
structures that evolve after the pandemic ends will also display various patterns deriving from 
pre-crisis specificities and the dynamic variables observed during the crisis. The former can be 
changed with a slow process, while the latter, once understood, may play a key role in spatial 
organization.  
Previous modeling studies from the 2003 SARS outbreak in mainland China, Hong 
Kong and Singapore, the 2009 H1N1 influenza pandemic in Taiwan as well as limited 
information from clinical reports from the 1957 Asian influenza pandemic, where R was 
estimated to be similar to COVID-19 provide different results and divergent aspects of effect 
estimation (101-105). Even using mathematical models for the very same SARS outbreak in 
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2005, the estimated effect of school closure was calculated to be very different from the disease 
transmission reduction (106). Studies modeling the COVID-19 pandemic (107-110) support 
the restriction measures including the closure of educational institutions at national levels, 
however literature data is gappy on the estimation of school closure intervention separately 
from other strict and the general social distancing control.  
Here we could draw conclusions that education institution closure as well as contact 
management strategies in schools populations cannot be seized or estimated as a homogenous 
effect on disease transmission. Different urban models with differing school population size, 
contact density and dynamics and additional different inhabitant population in the background 
can shape the infection transmissibility and its impact on epidemic progression significantly.  
In addition to the results gained from the modeling of the mitigation and suppression-
based strategies and the disease transmission network dynamics had a dire message too. If we 
can’t reduce the R value, we have no chance of finding a good solution to restart the lives of 
the population. Therefore, we concentrated on the methods which can help to decrease the R 
value. We revealed that the number of screening and testing could have large effects on 
mortality. Data showed that Germany is one of the most efficient European countries to keep 
the mortality rate low. Therefore we used their numbers as a reference point to estimate the 
optimal number of tests needed in Hungary. However, in order to be specific to the conditions 
of the regions, the number of tests likely to be required was corrected for each county by 
regional hospital capacities, such as ICU beds, the GDP, and the CHDI index. We must admit 
that our CHDI will need further modifications in the future.  
To provide the most detailed assistance to decision makers, we also analyzed the 
numbers of tests required to resolve the restrictions by region. In the current phase of the 
COVID-19 pandemic the proper diagnostic tool to identify individuals who can potentially 
communicate the infection is the polymerase chain reaction (PCR) based molecular assay 
which detects RNA target regions of the SARS-CoV-2 pathogen’s nucleic acid (111-113).  
Considering the capacities available for PCR 4,000-6,000 testing is the maximum limit 
of the successful feasibility calculated on the 18th of April, 2020. During the elaboration of a 
complex testing and screening strategy we aimed to fit it close to the accessibility rather than 
aiming to reach perfection. However, we would like to highlight that continuous effort should 
be made to strategically enhance the throughput of COVID-19 PCR testing and screening at 
this stage. Serological testing should also be a testing issue as the COVID-19 begins to subside 
to detect the immunized state of the population. Therefore, we recommended testing 
 35
approaches for symptomatic patients, healthcare professionals and highlighetd the importance 
of residential base representative screening.  
Similar to the European Commission, 4-5 high level groups of scientific advisors help 
the decision-makers in Hungary, so it is challenging to judge which analysis has a decisive 
impact on the final decisions. There were several similarities and differences in the analyses of 
the research groups. While, for example, the ITM Network Mathematical Epidemiology Group 
was primarily unique in the analysis of contact numbers, our multidisciplinary KETLAK 
consortium highlighted (1) the need for regional thinking and (2) the calculation of the effect 
of real health capacities on mortality scenarios.  
Importantly, it seems that the analyses described here and presented to the National 
Epidemiological Policy-Making Body could have major impact on governmental decision-
making since several of these suggestions has already taken effect before the submission of 
this article for publication. For example: 
 (1) previous considerations of the possible lifting of restrictions during the Easter 
holidays were rejected and lifting the restrictions were postponed for approximately a month 
(114), 
(2) regional variations of the epidemic have been introduced; restrictions will be eased 
in less densely populated areas while Budapest and surrounding area will remain under a more 
strict control,  
(3) the importance of increasing the number of testing has been recognized by the 
authorities, 
(4) a representative population screening study was recently initiated which involves 
more than 10000 volunteers and the concerted effort of the country’s four medical university 
(115).   
 In conclusion, in times of epidemics, the formation of interdisciplinary research groups 
is essential for policymakers, as none of the disciplines can model the complex problems that 
arise during an epidemic alone. The establishment, research activity and participation in 
decision-making of the KETLAK group can serve as a model for other countries, researchers 




IV.2. PERSONALIZED HEALTH EDUCATION AGAINST COVID-19 (PROACTIVE-19): 
PROTOCOL OF A RANDOMIZED CONTROLLED TRIAL  
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IV.2.1. Introduction 
World Health Organization (WHO) announced the COVID-2019 outbreak pandemic in 
the morning of 12 March 2020 (116). At the time of writing this study protocol, there are more 
than 770,000 confirmed cases with 37,000 fatalities across 178 countries, according to the 
Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, including 
447 cases and 15 deaths in Hungary. The tendency predicts that the epidemic is far from its 
peak (117).  
As often seen in the case of other epidemics, most cases can be asymptomatic or 
develop only mild symptoms and remain undiagnosed. Therefore, it is difficult to estimate the 
true incidence and the disease outcomes precisely (118) (119). However, early reports indicate 
that it may require ICU admission in 5-26%, due to acute respiratory distress syndrome 
(ARDS) in 17-20%, and overall mortality can rise to 11% of the recognised cases, mostly 
affecting the elderly (120-123).  
Significant efforts have been invested in research and development to re-target existing 
and discover new pharmacological treatments and preventive strategies against COVID-19 
(124), as indicated by the number of submitted protocols of the currently recruiting randomized 
trials on ClinicalTrials.gov. Nevertheless, it must be noted that we lack evidence-based targeted 
pharmacological therapy for prevention and treatment alike (125). None of the registered 
studies investigates the effects of lifestyle interventions in the prevention of poor outcomes in 
the COVID-19 epidemic. Advanced age and pre-existing comorbidities, such as cancer, 
cardiovascular disease, or diabetes mellitus, predispose to a more severe disease course and 
ICU admission (121, 126-128). 
The high risk of being infected with SARS-CoV-2 as well as the social distancing and 
quarantining as primary recommendations for the suppression of virus transmission may 
generate a high level of anxiety and mental stress (129, 130). In infected patients, better mental 
health might even have a positive impact on disease progression and survival (131, 132). 
Therefore, efforts for better coping with the aversive psychological states caused by the 
COVID-19 outbreak have high importance in mental health resilience. The role of lifestyle 
factors and fitness in the severity of COVID-19 has remained unexplored except for two recent 
studies. The history of smoking is independently associated with disease progression 
(OR=14.3, 95% CI: 1.6-25.0) in a Chinese cohort of 78 patients (133). Body mass index was 
>25 kg/m2 in 88% of patients who died as compared to 19% in survivors in another Chinese 
cohort of 112 patients (134). The latter seemingly contradicts the results of a very recent 
registry analysis of almost 100,000 participants where higher body mass index (indirectly, 
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better nutritional status) proved to be neutral or even preventive although against non-COVID-
19 upper airway infections (135). These suggest that personalized lifestyle interventions via 
education or counselling could be beneficial for COVID-19 outcomes. 
Our main objective is to evaluate the effects of a personalized multicomponent lifestyle 
intervention aiming to improve the outcomes of  COVID-19 infection in the population over 
60 years in a randomized clinical trial. The main hypothesis of PROACTIVE-19 is that the 
personalized multicomponent lifestyle intervention reduces the rate of our composite outcome 





The study protocol is structured following SPIRIT 2013 (136). PROACTIVE-19 is a 
pragmatic, randomized controlled clinical trial with adaptive "sample size re-estimation" 
design. This design allows interim analyses and necessary modifications of the sample size of 
the ongoing trial to ensure adequate power (137). 
 
Legislative amendment and ethical approval 
In Hungary, Act CLIV of 1997 on Health and Decree No. 23/2002 (of 9 May 2002) of 
the Minister of Health on Biomedical research on human individuals (as amended) stipulates 
the procedure for non-interventional investigation, according to which: 1) the leader of the 
investigation or the investigator shall inform the subject both verbally and in writing, before 
obtaining the consent of the subject to participate in the clinical research; 2) the participants' 
informed consent shall be written. This Act and Decree would not have allowed commencing 
the clinical trial as it would have amounted to a criminal offence. Based on our request sent to 
the Prime Minister of Hungary to amend the Decree, the Government of Hungary, issued 
Government Decree No. 63/2020 of 24 March 2020, according to which the new decree 
amends: 1) in addition to Section 159 of Act CLIV of 1997 on Health, subjects with full 
disposing capacities can be informed about the non-interventional investigation qualified as 
clinical research on coronavirus via means of telecommunications; 2) subjects may consent to 
participate in the clinical research through telecommunications; 3) subjects may withdraw their 
consent through telecommunications.  
Ethical approval: Scientific and Research Ethics Committee of the Hungarian Medical 
Research Council (IV/2428- 2 /2020/EKU). 
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Study population 
Inclusion and exclusion criteria 
The inclusion criteria of our selective primary prevention programme are: (1) age over 
60 years (that is, high-risk individuals), (2) informed consent to participate. The exclusion 
criteria are: (1) confirmed COVID-19 (active or recovered); (2) hospitalisation at screening for 
eligibility; (3) someone was already enrolled in the study from the same community/household 
(to avoid potential crosstalk between the study arms). 
 
Flow and timing 
A toll-free phone number will be available for all interested in participation. By dialling 
this number, the participant will be informed about the trial through a pre-recorded voice 
message, including the study rationale, conditions of participation, the process of the study, 
and the information on data protection. Willing participants will be redirected to an available 
operator, who will ascertain eligibility. Following verbal consent and randomization, the 
operator will obtain key personal information of the participants and all study-related 
information (Fig.1.). The allocation will not and can not be concealed from the operator, but it 
will be concealed from everyone else (participants, caregivers, outcome assessors). 
 
Interventions 
Participants will be randomized into two groups: (A) general health education; (B) 
personalized health education.  They will go through questioning and recommendations in 5 
domains: (1) mental health, (2) smoking habits, (3) physical activity, (4) dietary habits, and (5) 
alcohol consumption. Both groups will receive the same line of questioning to assess habits 
concerning these domains. 
Group A: questioning will be done in the order as mentioned above, followed by a general 
health education aiming towards improvement of these factors with general recommendations 
(the expected mean duration is approximately 10 min).  
Group B: questioning will be done in the same structured order, but an assessment of each 
domain will be followed by personalized recommendations (the expected mean duration is 
approximately 20 min). 
After the first contact, there will be follow-up calls in both groups, with a matching 
schedule: every week in the first month, every second week in the second month, then monthly. 
During these encounters, all change in all five domains since the last call will be assessed.  
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The operators will have received any healthcare education. Before enrolling 
participants, the operators will have to complete a standard training program consisting of 
seminars on the interventions held by medical professionals, followed by practice of scenarios. 
The operators will be trained not to give additional healthcare advice, and we will not secure 
other information sources, including electronic and printed material. 
 
Outcomes 
Based on literature data (120, 138), the primary endpoint will be defined as the 
composite of any of the followings in COVID-19 cases (an accredited laboratory should verify 
positivity) the rate of: 
1. ICU admissions   
2. hospital admissions (longer than 48 hours) for the following reasons 
o arrhythmia (causing hemodynamic instability and requiring continuous 
monitoring and/or cardiac support, as indicated by mean arterial pressure 65 
mm Hg, and/or serum lactate 2 mmol/L) and/or  
o ARDS (severe hypoxemic respiratory failure indicated by a PaO2/FiO2 300 
mm Hg according to the Berlin definition) (139) and/or  
o circulatory shock (the requirement of continuous vasopressor support to 
maintain mean arterial pressure 65 mmHg and/or serum lactate 2 mmol/L) 
and/or  
3. deaths. 
Secondary endpoints are the followings: 
1. the number of general practitioner visits,  
2. the number of emergency, hospital, and intensive care admissions;  
3. the LOH and ICU stay,  
4. the number of organ dysfunctions and failures (central nervous system, cardiovascular, 
respiratory, renal, liver, hematological),  
5. the measurable lifestyle changes (including physical and mental health), 
6. the costs of care. 
The primary and secondary outcomes will be assessed upon the conclusion of the trial, 
at least one year after the enrollment of the last participant. 
 
Randomization and blinding 
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Computer-generated random sequence randomization (central) will be performed, after 
giving informed consent. Due to the expected large sample size, we will use simple 
randomization. The allocation ratio will be 1:1. No stratification or blocking will be applied. 
In the study, participants will be blinded to the knowledge of the details of differences between 
the interventions. Everyone else (outcome assessors, caregivers, and data analysts) will be 
blinded regarding the allocation.  
 
Sample size calculation, interim and final analyses 
The primary outcome is estimated to occur in 20% of COVID-19-infected cases (≥60 
years of age) receiving the standard of care based on Chinese reports (120). Due to the lack of 
data, we hypothesised that our intervention would result in a 50% risk reduction. Considering 
one interim analysis on efficacy (with the Pocock correction), 90% power, 5% alpha 
(superiority design, two-sided), a dropout rate of 20% (140, 141) and assuming 10% incidence 
of COVID-19 in the target population, the estimated sample size is 3788 (rounded up to 3800) 
subject per study arm. The calculation was performed by Stata (version 15, Philadelphia, the 
USA). 
We plan to hold three interim analyses: the first for sample size re-estimation at 5% of 
the target sample size due to the dropout rate, the second for safety assessment at 10% of the 
target sample size and a third for efficacy assessment and sample size-reestimation at 50% of 
the target sample size. Early stopping will be executed if (1) safety concerns arise during the 
interim analysis, (2) the statistical power reaches at least 90% and p<0.05 at the efficacy interim 
analysis (stopping for benefit), (3) the statistical power does not reach 10%, p>0.05, and the 
event number does not reach the assumed 10% for the whole population at the efficacy interim 
analysis (that is, 380 events for the primary outcome - otherwise, the interim analysis is 
postponed and repeated when the event number reaches 380 events) (stopping for futility), (4) 
the consequences of the pandemic make further recruitment or follow-up impossible (stopping 
for unfeasibility). 
In the final analysis, the intention-to-treat analysis will be favoured over per-protocol 
(or "as-treated") analysis. We expect a full dataset for the primary endpoint (since the 
Hungarian Ministry of Interior will provide these data). If for any reason, data will be missing 
for the primary outcome, we will use available case analysis. The "last observation carried 
forward" strategy will be followed to impute missing data for other outcomes measured during 
the study. Missing more than one consecutive interventions after the initial assessment or 
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withdrawal of consent during follow-up result in the dropout of the patients unless 
hospitalisation is required in the meantime.  
In descriptive statistics, the count and percentage will be provided for each treatment 
arm for binary outcomes. For continuous outcomes, n, mean, median, interquartile (Q3–Q1), 
standard deviation, minimum, and maximum values will be provided for each treatment arm. 
In a univariate comparative analysis, we will calculate relative risk with 95% confidence 
interval (CI) when comparing the primary endpoint between two groups (alpha=5%) with a 
reference arm using non-repeated intervention complemented with chi-square or Fisher's exact 
test (the same strategy will be followed for binary secondary outcomes). For continuous 
variables, we will use t-test assuming unequal variances or the Mann-Whitney test. We will 
perform univariate (Kaplan-Meier and Cox-regression) and multivariate (Cox-regression) 
survival analysis for binary outcomes. An adjustment will be carried out at least for age, sex, 
and education. Mixed effect logistic regression will be conducted to estimate the effect of the 
multicomponent intervention on the outcomes, where the subject IDs will be used as a random 
subject. The model will be adjusted for changes in smoking habits, alcohol consumption, 
physical activity, and dietary habits (or body mass index). 
All analyses will be carried out with SPSS version 26 and Stata version 15. 
 
Study duration 
The planned starting date of the study is 1 April 2020, and the anticipated finishing date 
is the end of the pandemic or development of the vaccine, but no more than one year from the 
enrolment of the last participant. 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation Close-out 
TIMEPOINT 0 0 0 
Weekly in 
the 1st month 
Every second week in 
the 2nd month 
Monthly from the 
3rd month 
1 year* 
ENROLMENT        
Eligibility screen X       
Informed consent X       
Randomization  X      
INTERVENTIONS:        
Intervention A 
General guidance 
  X X X X X 
Intervention B 
Personalized guidance 
  X X X X X 
ASSESSMENTS:        
Questionnare   X X X X X 
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Table 9: Schedule of enrollment, interventions, and assessments according to the SPIRIT statement. The 
asterisk indicates that the anticipated finishing date is the end of the pandemic or development of the vaccine, 
but no more than 1 year from the enrolment of the last participant 
 
Data management  
Data handling 
Confidential and anonymous data handling will be performed by the Data Monitoring 
Committee (DMC). To be able to trace data to an individual subject, a subject identification 
code list will be used. A Personal Identification Number will be generated to identify the data 
of the participant. This Personal Identification Number will be present on all forms and 
documents of each individual. Electronic case report forms (eCRFs) will be used. The 
Investigator will ensure that the data in the eCRFs are accurate, complete, and legible. Detailed 
data flow will be described in a Data Management Plan. Data from completed eCRFs will be 
validated under the direction of the Data Manager on the DMC according to a Data Cleaning 
Plan. Any missing, implausible, or inconsistent recordings in the eCRFs will be referred back 
to the Investigator using a data query form. They will be documented for each subject before 
clean file status is declared. All changes to eCRFs will be recorded.  
The DMC will perform an independent assessment of trial-related documents and 
activities to ensure respect for subjects' right, safety and well-being and to guarantee the 
plausibility of clinical data. The similarity of groups at baseline will also be checked.  
Written informed consent had to be replaced, due to the specific circumstances (the need to 
maintain social distance during the pandemic), by verbal consent obtained during the first call 
on recruitment. The verbal consent to participate in such clinical research had not been 
permitted by the law previously. Therefore, the bill was amended on 24/03/2020 upon the 
request of our study consortium. This amendment enabled us to conduct this trial. 
After verbal consent of the subjects, the data will be recorded by the investigator. 
Clinical research data are processed separately from participants' data under pseudonyms. Data 
may only be accessed by persons acting under the authority of the controller and in accordance 
with the authorisation system established within the controller's organisational structure, only 
to the extent and in the manner necessary for the performance of tasks. Personal data are not 




Due to the nature of the multicomponent moderate-intensity lifestyle intervention, we 
do not expect serious adverse events. However, minor or moderate adverse events may 
develop, such as alcohol and nicotine withdrawal, weight change exceeding the optimum, and 
the need for change in regular medications (antihypertensive or antidiabetic drugs). Participants 
will be advised to consult their primary care physician if any non-lifestyle-related health issue 
arises except for COVID-19-related concerns when the call will be transferred to the COVID-
19-specific national helpline immediately. If a participant develops a potentially serious health 
problem, the chairman of the Safety Monitoring Board (LC) will be notified. After the first 
interim analysis for safety at 10% of the target number, the board will revise the charts of all 
visits to health facilities and assess if any event is related to the interventions (see, early 
stopping for safety).  
 
IV.2.3. Discussion 
Neither the worldwide climax of the COVID-19 pandemic can be foreseen nor the 
potential repeated outbreaks (117). Although efforts of primary prevention (i.e. vaccine 
development) are promising, it is expected to take 12-18 months from now on (142). Better 
lifestyle has its unquestionable advantages not only for infectious but also for common chronic 
diseases including diabetes mellitus, chronic heart failure or malignant tumours. Considering 
the recent low numbers of reported cases and the expected trajectory of the epidemic in 
Hungary, it seems that we are still on time to seek for personalized and easily available public 
health interventions applicable for the target population.  
While in the United States, "remote" consent via telecommunication may be possible, 
the Hungarian laws have not allowed such initiatives until now. An outbreak imposes new 
challenges to the process of ethical approval (143). Most importantly, the instant reaction of 
both the researchers and the ethical committees is essential, while preserving the validity of 
scientific content (144). 
Based on the results of the current study, such strategies could be introduced in other 
countries. Lifestyle counselling is expected to reduce mental distress, smoking and alcohol 
consumption, increase physical activity and favourably change the body mass (along with the 
body composition). As the main results of all these, the interventions may boost the body's 
cardiovascular and pulmonary reserve capacities, leading to improved resistance against the 
damage caused by COVID-19. Consequently, lifestyle changes can reduce the incidence of 
life-threatening conditions and attenuate the detrimental effects of the pandemic seriously 
affecting the older population.   
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Strengths and limitations 
We aim to apply lifestyle interventions considered to be safe in a broad population of 
subjects exposed at high risk of a severe course of COVID-19. The expected health benefits of 
the interventions considerably exceed its potential harms. With this study design, we can 
evaluate the effectiveness of (1) the offer of lifestyle intervention vs (2) that of the actual uptake 
of or compliance to the lifestyle intervention. We expect that the moderate intensity of the 
personalized multicomponent lifestyle intervention will maximise the effectiveness and, at the 
same time, prevents low adherence. In addition to the expected beneficial effects regarding the 
infection, other protective changes are likely regarding cardiovascular and malignant morbidity 
and mortality on the long-term. The interventions are easy to be delivered while being 
affordable and implementable for the vast majority of the population.  
We expect that there will be limitations in this study (145). We define cross-
contamination that participants on different arms deliberately and unknowingly communicate 
with each other, leading to the loss of the true effect of lifestyle interventions. To minimise the 
risk of cross-contamination, we decided to include only one subject from communities with 
multiple potential candidate participants. Although we can evaluate the actual uptake of the 
lifestyle interventions, its validity is uncertain due to the patient-reported nature of the data. 
We cannot anticipate the climax of the epidemics so that the infection rate of the target 
population may deviate from the assumed 10%. To overcome this, we use sample size-
readjustment adaptive design, which may settle the problem with the unpredictable dropout 
rate as well (although this method cannot counteract chronological changes in the dropout rate 
throughout the evolution of the pandemic). All data on secondary outcomes are provided by 
participants and other, less reliable indirect data sources. We anticipate that volunteers give a 
representative sample of the target population, but we cannot exclude that our study population 
will be somewhat better educated and highly motivated. Despite the thorough training of the 
operators, inter-operator variability may be present. 
 
Additional information and plans 
A follow-up study (PROACTIVE-19 PLUS) is planned to follow up patients, in which 
blood samples (serum and plasma) from every patient will be stored to analyse 
immunoglobulins later if required and to build a biobank for a future clinical study. We also 
intend to publish the study protocol.  
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V. SUMMARY AND NEW DISCOVERIES 
Chapter III. Glucose level independently and dose-dependently worsens acute pancreatitis: A 
cohort analysis 
- We established that increasing on-admission and peak in-hospital glucose is associated 
with increasing AP severity and mortality, independently of age, gender, DM and AP 
etiology. 
- We saw a dose-dependent association not only with severity and mortality, but also 
with LOH and complications. In light of the available literature, this suggests that serum 
glucose might be a pancreatotoxic agent. 
- A trend was seen with increasing HbA1c and AP severity and complications 
- Based on these conclusions, we formulated the following implications for practice: 
o 1. Prevention: Maintaining a normal glucose homeostasis might reduce the risk 
of severe AP and local complications. 
o 2. Prognosis: Increased on-admission glucose has a dose-dependent association 
with increasing severity, mortality, LOH and complications of AP.  
o 3. Prompt treatment: High peak glucose is dose-dependently associated with a 
higher rate of severe cases, mortality, systemic complications and increased 
LOH. Hyperglycemia does not necessarily present on admission, monitoring 
serum glucose during the course of AP is crucial. Adequate in-hospital control 
of hyperglycemia can greatly contribute to the treatment of AP.  
 
Chapter IV. Translational medicine in the COVID-19 pandemic 
- We formed an interdisciplinary team (KETLAK) to help contain the COVID-19 
pandemic in Hungary – we think that formation of such teams is crucial to aid 
government decision makers. No single discipline can tackle such a complex problem 
alone. 
- We analyzed the international state of the COVID-19 pandemic, performed 
mathematical models for the course and dynamics, also accounting for territorial 
patterns, economic, social and healthcare related factors.  
- These information were regularly delivered to the government and policy makers to 
help combat the pandemic. 
- The KETLAK group could serve as a model for other countries and for future epidemics 
as well. 
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- Noticing a gap in the available evidence, we planned and initiated a RCT. The 
PROACTIVE-19 trial will show the benefits of a telephone-based, personalized, 
multicomponent lifestyle intervention in COVID-19. 
- Based on positive results, a similar strategy could be applied in other countries, not only 
for COVID-19, but for other diseases as well.  
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